Thanks Andreas. I think indeed it is important to have the option of using the MITO regimen because QOL with this regimen was better (that was the first primary endpoint of MITO7 and planned in 350 patients) and because 4 trials (MITO7, ICON8, GOG262 and the Turbo study of Maria van der Burg) all showed a – non-significant – but somewhat higher PFS in the weekly arms. Anyhow no signal that PFS is worse with weekly.

Indeed with paclitaxel weekly 80 mg/m² the QOL data are worse (e.g. ICON8) but this is the opposite with the MITO7 regimen using 60 mg/m² paclitaxel in combination carbo AUC2 weekly.  Based on this evidence, many BGOG centres (and I suppose also MITO centers and others?) have shifted to the MITO7 regimen in first line (and it is an option for the standard arm in the ENGOT-ov43).

Also, hair loss Grade 2 was significantly lower in MITO7 study (weekly 29%, 3-weekly 59%) In addition, in our experience when using the MITO7 regimen in combination with cold caps, 96% of our patients do not need  a wig.  Something the majority of our patients value very high.

Finally I believe that for Japanese (Asian?) patients the JGOG regimen should still be an option.

• This reply was modified 4 years, 10 months ago by Ignace Vergote.